Navigation Links
VTT and GE Healthcare developing novel biomarkers to predict Alzheimer's disease
Date:6/26/2012

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer's disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

Alzheimer's disease (AD) is a growing challenge to the health care systems and economies of developed countries with millions of patients suffering from this disease and increasing numbers of new cases diagnosed annually with the increasing ageing of populations.

Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer's disease may also help in identifying new therapeutic avenues.

In 2010 GE Healthcare entered into "biosignatures initiative" alliance with Janssen Pharmaceutica N.V. (Janssen) to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

VTT's research professor Matej Oreič said: "We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE's and Janssen's biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options."


'/>"/>

Contact: Sampo Sammalisto
sampo.sammalisto@vtt.fi
358-505-841-100
VTT Technical Research Centre of Finland
Source:Eurekalert

Related biology news :

1. BGI, GE Healthcare team up on pioneering stem cell science projects
2. Premier Healthcare Renews Supplier Agreement with Masimo
3. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
4. Bioethics for Beginners: 60 Cases and Cautions from the Moral Frontier of Healthcare
5. Boston Healthcare Associates Roundtable Explores Challenges and Opportunities Surrounding the Value of Big Data within the Life Sciences
6. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
7. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
8. Agricultural expert outlines path for developing nations to double food production, meet 2050 demand
9. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
10. Research4Life greatly expands peer-reviewed research available to developing world
11. Family history of liver cancer increases risk of developing the disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... /PRNewswire/ -  Equicare Health Inc ., the leading supplier ... one of the top 100 companies in the 2016 ... distinguishes the top digital health companies across the globe. ... this year continually upgrading our product with the ongoing ... team," says Len Grenier , CEO of Equicare ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader ... the implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance ... Cambridge, MA. , The event follows the successful November 15th event that ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, ... for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively ... review, the names earlier proposed by the discoverers have been approved by the IUPAC ...
Breaking Biology Technology: